前列腺癌患者中超低分割全盆腔放疗(WPRT)与传统分割WPRT耐受性是否相当?HOPE试验早期结果
HOPE试验是一项2期多机构随机对照试验,纳入80例局限前列腺癌且NCCN不良中危、高危或极高危患者,1:1随机接受传统分割或超低分割全盆腔放疗,所有患者先接受15 Gy HDR近距离治疗 boost。超低分割WPRT在急性期耐受良好,急性不良事件率无显著差异,无4级不良事件或治疗相关死亡,且对EPIC-50肠道QOL领域的不利影响更小。
要点
- 超低分割WPRT急性期耐受良好,两臂急性不良事件率无显著差异,无4级不良事件或治疗相关死亡。
- 超低分割WPRT对EPIC-50肠道总分、功能及困扰领域的不利影响小于传统分割WPRT。
- 更多超低分割WPRT患者达到EPIC-50泌尿领域的临床最小重要差异。
核心结论
- HDR-BT后超低分割WPRT在急性期是耐受良好的治疗策略,与传统分割WPRT相比对肠道QOL领域的不利影响更小。
研究设计与样本
- HOPE试验为2期多机构随机对照试验,纳入80例局限前列腺癌且NCCN不良中危、高危或极高危患者,来自3家加拿大机构。
- 患者按1:1随机接受传统分割WPRT(标准臂)或超低分割WPRT(试验臂),所有患者先接受15 Gy HDR-BT单次boost。
- 传统分割WPRT为45 Gy分25次每日或46 Gy分23次,超低分割WPRT为25 Gy分5次隔日照射。
- 急性毒性在放疗期间及治疗后6周采用临床医生报告的CTCAE v5.0评估,QOL采用EPIC-50和IPSS评估。
主要发现
- 共80例患者入组并接受治疗,传统分割臂39例、超低分割臂41例接受外照射WPRT。
- 除超低分割臂2例外,所有患者均接受雄激素剥夺治疗;两臂基线临床特征相似,51例(63.8%)为高危或极高危前列腺癌。
- 两臂急性不良事件率无显著差异,未报告4级不良事件或治疗相关死亡。
- 急性期超低分割WPRT对EPIC-50肠道总分、功能及困扰领域评分的不利影响小于传统分割WPRT。
- 更多超低分割WPRT患者达到EPIC-50泌尿领域的临床最小重要差异;性功能和激素领域两臂QOL无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this work was to evaluate the acute toxicity and quality-of-life (QOL) impact of ultrahypofractionated whole pelvis radiation therapy (WPRT) compared with conventional WPRT fractionation after high-dose-rate prostate brachytherapy (HDR-BT). METHODS AND MATERIALS: The HOPE trial is a phase 2, multi-institutional randomized controlled trial of men with prostate-confined disease and National Comprehensive Cancer Network unfavorable intermediate-, high-, or very-high-risk prostate cancer. Patients were randomly assigned to receive conventionally fractionated WPRT (standard arm) or ultrahypofractionated WPRT (experimental arm) in a 1:1 ratio. All patients underwent radiation therapy with 15 Gy HDR-BT boost in a single fraction followed by WPRT delivered with conventional fractionation (45 Gy in 25 daily fractions or 46 Gy in 23 fractions) or ultrahypofractionation (25 Gy in 5 fractions delivered on alternate days). Acute toxicities measured during radiation therapy and at 6 weeks posttreatment were assessed using the clinician-reported Common Terminology Criteria for Adverse Events version 5.0, and QOL was measured using the Expanded Prostate Cancer Index Composite (EPIC-50) and International Prostate Symptom Score (IPSS). RESULTS: A total of 80 patients were enrolled and treated across 3 Canadian institutions, of whom 39 and 41 patients received external radiation therapy with conventionally fractionated and ultrahypofractionated WPRT, respectively. All patients received androgen deprivation therapy except for 2 patients treated in the ultrahypofractionated arm. The baseline clinical characteristics of the 2 arms were similar, with 51 (63.8%) patients having high or very-high-risk prostate cancer disease. Treatment was well tolerated with no significant differences in the rate of acute adverse events between arms. No grade 4 adverse events or treatment-related deaths were reported. Ultrahypofractionated WPRT had a less detrimental impact on the EPIC-50 bowel total, function, and bother domain scores compared with conventional WPRT in the acute setting. By contrast, more patients treated with ultrahypofractionated WPRT reached the minimum clinical important difference on the EPIC-50 urinary domains. No significant QOL differences between arms were noted in the sexual and hormonal domains. CONCLUSIONS: Ultrahypofractionated WPRT after HDR-BT is a well-tolerated treatment strategy in the acute setting that has less detrimental impact on bowel QOL domains compared with conventional WPRT.
引用
- Mendez LC, Crook J, Martell K, et al. Is Ultrahypofractionated Whole Pelvis Radiation Therapy (WPRT) as Well Tolerated as Conventionally Fractionated WPRT in Patients With Prostate Cancer? Early Results From the HOPE Trial. Int J Radiat Oncol Biol Phys. 2023. PMID: 38072323. doi:10.1016/j.ijrobp.2023.11.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。